Imatinib Resistance Mutation Analysis - Kinase Domain Test Cost & Procedure

What is analysis of imatinib resistance mutations?

The most often described mechanism for imatinib resistance is the emergence of mutations in the Abl kinase domain. It has been suggested that the source of resistance for many kinase-domain mutations is a direct interference with drug binding.

ABL kinase domain: What is it?

Patients with chronic myeloid leukemia (CML) who do not respond well to tyrosine kinase inhibitors are thought to benefit from clinical decision algorithms that take into account their BCR-ABL1 kinase domain (KD) mutation status (TKIs).

What is the most typical CML mutation?

The majority of nonresponsive patients with CML have mutations in the kinase domain (KD) of ABL1, which are responsible for the most well-studied mechanisms of TKI resistance.

The occurrence of point mutations, which represent a single aa substitution in the kinase domain, which impair drug binding by affecting crucial residues for direct contact with the TKI or by preventing BCR-ABL1 from assuming the inactive state, is the mechanism of acquired resistance to imatinib that is most frequently described.

ABL1 has nuclear localization signals and a DNA binding domain that it employs to mediate DNA damage-repair capabilities, while ABL2 has increased actin and microtubule binding capacity to boost its cytoskeletal remodeling functions.

What does BCR-ABL mutation analysis entail? The fusion of the two genes BCR and ABL leads in the mutation known as BCR-ABL. It's referred to be a fusion gene by some. Chromosome 22 is normally where the BCR gene is found. Chromosome 9 is normally home to the ABL gene. When pieces of the BCR and ABL genes separate and switch locations, the BCR-ABL mutation results.

 What does a BCR-ABL result that is positive mean? The diagnosis of B-lymphoblastic leukemia/lymphoma and a form of acute lymphoblastic lymphoma (ALL), especially CML, is confirmed.

Rarely, occurrences of acute myeloid leukemia and T-lymphoblastic leukemia/lymphoma are associated with the defective chromosome.

How can CML be verified?

a blood test.

Before any symptoms appear, a complete blood count (CBC) blood test is typically used to identify CML in the majority of patients. A CBC is frequently performed as part of a routine medical examination. White blood cell counts are high in those who have CML.

What type of diagnostic finding characterizes CML?

An abnormal white blood cell count is the most typical indicator of CML and is frequently discovered during blood tests for unrelated medical conditions or during a routine examination. Doctors examine blood and bone marrow cells using a number of tests to determine the presence of CML.

Which CML stage offers the best outlook?

While the rapid and blast phases provide more noticeable symptoms, the chronic phase may produce few or no symptoms. The likelihood of a successful treatment plan increases if CML can be identified and treated by doctors during the chronic phase.